Kelley Anne Saia, MD
Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Obstetrics & Gynecology

MD, University of Vermont
BSN, Georgetown University
BA, Hobart and William Smith Colleges



Expertise includes: Treatment of substance use disorders in pregnancy and post-pregnancy, including opioid, alcohol, stimulant and marijuana use disorders; Trauma-informed care for pregnant persons with substance use disorder

Diversity, Equity, Inclusion and Accessibility

Our team at Project RESPECT is actively engaged in DEI&A for pregnant and post-pregnant persons of color with substance use disorders. We have received funding from Massachusetts Department of Public Health (2015), Boston Medical Center's Grayken Center for Addiction Treatment (2018), Massachusetts Bureau of Substance Abuse Services (2019), and Massachusetts Attorney General’s Office (2019) to initiate and expand this work. These funds have enabled our team to grow in numbers and diversity. From 2015 to 2022, grant funded initiatives focused on improving access to addiction treatment for pregnant BIPOC has allowed our team to expand from 6 to 14 members, and improve racial and ethnic diversity from 32% BIPOC members to 43% reflecting the communities of color which we serve. We have conducted qualitative research focused on identifying systemic barriers within our clinic which prevent access or lower engagement in treatment for pregnant persons of color. We have initiated community linkages with two residential treatment programs in Boston for pregnant women of color and provide weekly on-site recovery groups hosted by RESPECT team members from the respective communities. We have increased the percentage of pregnant BIPOC who engage in Project RESPECT services from 13% to 20%; and 70% of post-pregnant BIPOC clients remain in care with our team. We strive to improve our obstetric and addiction recovery care and our infrastructure to decrease barriers and advance supports for pregnant and post-pregnant BIPOC with substance use disorders.



OBOT Project RESPECT
01/01/2025 - 06/30/2026 (Subcontract PI)
PI: Kelley Anne Saia, MD
Massachusetts Dept. of Public Health / DPH HHS SAMHSA

SOR3 (renewal of SOR 2)
07/01/2023 - 06/30/2025 (Subcontract PI)
PI: Kelley Anne Saia, MD
Massachusetts Dept. of Public Health / DPH HHS SAMHSA


Office based Opioid Treatment (OBOT)/Project RESPECT
07/01/2018 - 12/31/2024 (PI)
Massachusetts Dept. of Public Health / DPH


Project RESPECT - OBOT Expansion Grant / MASS SOR
04/01/2021 - 06/30/2024 (Subcontract PI)
PI: Kelley Anne Saia, MD
Massachusetts Dept. of Public Health / DPH HHS SAMHSA


Project RESPECT
01/01/2021 - 12/31/2023 (PI)
MA Office of Attorney General


RFR for Neonatal Abstinence Syndrome (NAS) Interventions Inpatient Technical Assistance Program
05/10/2021 - 09/30/2023 (Subcontract PI)
PI: Kelley Anne Saia, MD
Beth Israel Deaconess Medical Center Mass HlthPolicy Comm


Entre Familia (PPW)
01/01/2018 - 09/29/2023 (Subcontract PI)
PI: Kelley Anne Saia, MD
Boston Public Health Commission HHS SAMHSA


Office based Opioid Treatment (OBOT)/Project RESPECT (Renewal)
11/08/2021 - 06/30/2023 (PI)
Massachusetts Dept. of Public Health / DPH


Office Based Opioid Treatment
08/15/2007 - 06/30/2010 (PI)
DPH


Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Iannella N, Momper J, Mirochnick M, Suhandynata RT, Saia K, Werler M, Jones HE, Wachman EM. Pharmacokinetics of Oral and Extended-release Naltrexone in Pregnant and Lactating Individuals and their Infants. J Addict Med. 2025 May 19.View Related Profiles. PMID: 40388713
     
  2. Nelson-Rodriguez A, Saia K, Xie X, Momper J, Schiff DM, Wachman EM. Pharmacokinetics and Breast Milk Transfer to Infants of Subcutaneous Extended-Release Buprenorphine for the Treatment of Individuals with Opioid Use Disorder. Breastfeed Med. 2025 May 13.View Related Profiles. PMID: 40358655
     
  3. Sousa A, Besong OTO, Wachman EM, Taglauer ES, Beane JE, Kefella Y, Koo JS, Saia K, Jones HE, Zhang H. Placental transcriptome analysis in opioid-exposed versus non-opioid exposed pregnancies. Placenta. 2025 Mar 25; 162:27-34.View Related Profiles. PMID: 39983471; PMCID: PMC11908891; DOI: 10.1016/j.placenta.2025.02.012;
     
  4. Khazanchi R, Wachman EM, Schiff DM, Modest A, Saia KA, Hsu HE. Mandatory Child Protective Services Reporting for Substance-Exposed Newborns and Peripartum Outcomes: A Difference-in-Differences Analysis. JAMA Pediatr. 2024 Jul 01; 178(7):719-722.View Related Profiles. PMID: 38709513; PMCID: PMC11074925; DOI: 10.1001/jamapediatrics.2024.0903;
     
  5. Mantri S, Cheng AC, Saia K, Shrestha H, Amgott R, Bressler J, Werler MM, Carter G, Jones HE, Wachman EM. Neurobehavioral outcomes of infants exposed to buprenorphine-naloxone compared with naltrexone during pregnancy. Early Hum Dev. 2024 Jul; 194:106051.View Related Profiles. PMID: 38815498
     
  6. Wachman EM, Saia K, Bressler J, Werler M, Carter G, Jones HE. Case Series of Individuals Treated With Naltrexone During Pregnancy for Opioid and/or Alcohol Use Disorder. J Addict Med. 2024 May-Jun 01; 18(3):288-292.View Related Profiles. PMID: 38354121; PMCID: PMC11150101; DOI: 10.1097/ADM.0000000000001293;
     
  7. Harris M, Schiff DM, Saia K, Muftu S, Standish KR, Wachman EM. Academy of Breastfeeding Medicine Clinical Protocol #21: Breastfeeding in the Setting of Substance Use and Substance Use Disorder (Revised 2023). Breastfeed Med. 2023 Oct; 18(10):715-733.View Related Profiles. PMID: 37856658; PMCID: PMC10775244; DOI: 10.1089/bfm.2023.29256.abm;
     
  8. Deflorimonte C, Glissendorf V, Hofer J, Cai A, Iannella N, Boateng JO, Carter G, Saia KA, Jones HE, Wachman EM. National Provider Survey: Use of Naltrexone for Pregnant Individuals with Substance Use Disorders. J Addict Med. 2023 Nov-Dec 01; 17(6):736-738.View Related Profiles. PMID: 37934548; PMCID: PMC10873530; DOI: 10.1097/ADM.0000000000001225;
     
  9. Deflorimonte C, Glissendorf V, Hofer J, Cai A, Iannella N, Boateng JO, Carter G, Saia KA, Jones HE, Wachman EM. National Provider Survey: Use of Naltrexone for Pregnant Individuals with Substance Use Disorders. J Addict Med. 2023 Sep 20.View Related Profiles. PMID: 37729010
     
  10. Valentine SE, Godfrey LB, Gellatly R, Paul E, Clark C, Giovannini K, Saia KA, Nillni YI. Supporting the implementation of written exposure therapy for posttraumatic stress disorder in an obstetrics-substance use disorder clinic in the Northeastern United States. SSM Ment Health. 2023 Dec 15; 4.View Related Profiles. PMID: 38645900; PMCID: PMC11027481; DOI: 10.1016/j.ssmmh.2023.100256;
     
Showing 10 of 44 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 44 publications over 16 distinct years, with a maximum of 7 publications in 2018 and 2023

YearPublications
20071
20111
20121
20131
20142
20151
20162
20172
20187
20193
20202
20214
20224
20237
20243
20253


Can New Medication Styles for Opioid Addiction Prevent Relapse in New Parents?

HealthCity 9/22/2022

BMC Launches First Maternal Health Addiction Fellowship

HealthCity 4/19/2022

Can Parenting Interventions Help Mothers with OUD and Their Babies?

HealthCity 7/13/2021

Mandatory Reporting Law Is Harmful for Pregnant People with Substance Use Disorder

HealthCity 6/29/2021

Support for Newborn Mothers with Opioid Use Disorder Doesn't Go Far Enough

HealthCity 6/2/2021
Contact for Mentoring:

85 E. Concord St
Boston MA 02118
Google Map

617.414.7314
Download vCard

Saia's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
See all (144) concept(s)
_
Media Mentions
_
Co-Authors
See all (59) people
_
Similar People
See all (60) people
_
Same Department
Search Department